Skip to content
HowShorted

Taysha Gene Therapies, Inc. short interest in 2021

In 2021, Taysha Gene Therapies, Inc.'s disclosed short interest ran from 3.34% of shares outstanding on 15 Jan 2021 to 7.83% on 31 Dec 2021, a change of +4.49 percentage points. The year's high was 7.83% on 31 Dec 2021 and its low 3.04% on 29 Jan 2021, averaging 5.34% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 46.05 days on 13 Aug 2021. Full history: Taysha Gene Therapies, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Taysha Gene Therapies, Inc. in 2021

2021 in figures

Start of year
3.34% (15 Jan 2021)
End of year
7.83% (31 Dec 2021)
Change
+4.49 pp
High
7.83% (31 Dec 2021)
Low
3.04% (29 Jan 2021)
Average
5.34%
Highest days to cover
46.05 (13 Aug 2021)
SEC filings marked
8

Every report in 2021

Taysha Gene Therapies, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20213.34%10.01
29 Jan 20213.04%15.20
12 Feb 20213.45%32.85
26 Feb 20213.45%37.09
15 Mar 20213.52%21.8610-K filed, results (8-K)
31 Mar 20213.79%17.33
15 Apr 20213.51%7.35
30 Apr 20213.57%33.40
14 May 20213.75%19.6310-Q filed, results (8-K)
28 May 20214.14%8.98
15 Jun 20213.67%6.71
30 Jun 20215.02%5.64
15 Jul 20216.60%10.58
30 Jul 20217.32%20.13
13 Aug 20217.26%46.05
31 Aug 20217.24%30.7010-Q filed, results (8-K)
15 Sep 20217.23%36.29
30 Sep 20217.49%24.19
15 Oct 20216.64%39.96
29 Oct 20216.35%12.69
15 Nov 20216.65%10.8810-Q filed, results (8-K)
30 Nov 20216.72%14.51
15 Dec 20216.62%15.72
31 Dec 20217.83%13.13

See also: Taysha Gene Therapies, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.